SOLV says HIS separation keeps 4%-5% organic growth target to 2028
Management said the HIS separation is for strategic focus on medtech, keeping RemainCo’s 4%-5% organic growth target by 2028 intact. Margin dilution is expected, with efficiencies and new launches supporting MedSurg and Dental margin and EPS expansion.